- CITATIONS: 1
|Application ||WB, IHC-P, FC, E|
|Calculated MW||27131 Da|
|Antigen Region||211-239 aa|
|Other Names||Diablo homolog, mitochondrial, Direct IAP-binding protein with low pI, Second mitochondria-derived activator of caspase, Smac, DIABLO, SMAC|
|Target/Specificity||This SMAC antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 211-239 amino acids from the C-terminal region of human SMAC.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.|
|Precautions||SMAC Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Promotes apoptosis by activating caspases in the cytochrome c/Apaf-1/caspase-9 pathway. Acts by opposing the inhibitory activity of inhibitor of apoptosis proteins (IAP). Inhibits the activity of BIRC6/bruce by inhibiting its binding to caspases. Isoform 3 attenuates the stability and apoptosis- inhibiting activity of XIAP/BIRC4 by promoting XIAP/BIRC4 ubiquitination and degradation through the ubiquitin-proteasome pathway. Isoform 3 also disrupts XIAP/BIRC4 interacting with processed caspase-9 and promotes caspase-3 activation. Isoform 1 is defective in the capacity to down-regulate the XIAP/BIRC4 abundance.|
|Cellular Location||Mitochondrion. Note=Released into the cytosol when cells undergo apoptosis|
|Tissue Location||Ubiquitously expressed with highest expression in testis. Expression is also high in heart, liver, kidney, spleen, prostate and ovary. Low in brain, lung, thymus and peripheral blood leukocytes. Isoform 3 is ubiquitously expressed|
Provided below are standard protocols that you may find useful for product applications.
SMAC is an inhibitor of apoptosis protein (IAP)-binding protein. This mitochondrial protein enters the cytosol when cells undergo apoptosis, and it moderates the caspase inhibition of IAPs.
Carbone,A., et.al., Genes Chromosomes Cancer 47 (12), 1067-1075 (2008)
If you have any additional inquiries please email technical services at email@example.com.